ArticleCureus2024
Osteopenic Effect of Disulfiram Therapy in Patients With Alcohol Use Disorder.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDisulfiram is widely used to treat alcohol use disorder. Alcohol per se adversely affects bone health. In the experimental study, disulfiram leads to apoptosis of osteoblast and significant osteopenia in adult rats. The present study explored the possibility of the occurrence of similar osteopenic effects of disulfiram therapy in patients with alcohol use disorder.
aimTo assess the impact of disulfiram on bone health in patients with alcohol use disorder. DESIGN AND
methodsThe study design was longitudinal observational. Subjects included 40 males with alcohol use disorder (aged 35.7±7.1 years, body mass index: 23.4±3.8 kg/m
resultsThe median (interquartile range) duration of alcohol use and alcohol use disorder were 15.0 (10.0-20.0) and 8.0 (5.0-12.0) years, respectively. Patients had taken disulfiram for a mean period of 225±109 days, with 65% therapeutic adherence. Serum transaminases improved significantly during follow-up, indicating abstinence from alcohol intake. Despite alcohol withdrawal, lumbar spine bone mineral density decreased significantly at the final follow-up (0.942±0.105 gm/cm
conclusionsThis study highlights a significant reduction in lumbar-spine bone mineral density and an increase in the β-CTx/osteocalcin ratio in patients with alcohol use disorder undergoing disulfiram therapy. These findings suggest that, despite the benefits of alcohol cessation facilitated by disulfiram, there is a notable risk of osteopenia that warrants careful monitoring. Clinicians should consider regular bone health assessments and proactive measures to mitigate bone density loss in this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.